Alnylam Pharmaceuticals, Inc.
ALNY· Nasdaq
ALNYAlnylam Pharmaceuticals, Inc.
Source filing unavailable
| Metric | Q4 2013 | Q4 2012 | Q4 2011 | Q4 2010dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | — | — | $21.19M |
| Net Income | -$32.36M | -$62.19M | -$14.30M | -$6.93M |
| EPS Diluted | -$0.51 | -$1.20 | -$0.33 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Alnylam Pharmaceuticals, Inc. · CIK 1178670 · Engraved from SEC EDGAR
